British Journal of Clinical Pharmacology · 2016 · 31 citations · 33 references
MedicinePharmacologyToxicologyDrug MetabolismHepatotoxicologyMechanisms Of ToxicityCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug ToxicityDrug-metabolizing EnzymesHepatic Drug MetabolismHepatotoxicity MechanismsCytochrome P450 BioactivationCytochrome P450 Drug MetabolismCytochrome P450 Enzyme ActivityCytochrome P450 Human Liver MicrosomesCytochrome P450 KineticsCytochrome P450 Metabolic PathwaysCytochrome P450 Reaction MechanismsDrug Bioactivation
Aims Oxidative bioactivation of amodiaquine (AQ) by cytochrome P450s to a reactive quinoneimine is considered as an important mechanism underlying its idiosyncratic hepatotoxicity. However, because internal exposure to its major metabolite N‐desethylamodiaquine (DEAQ) is up to 240‐fold higher than AQ, bioactivation of DEAQ might significantly contribute to covalent binding. The aim of the present study was to compare the kinetics of bioactivation of AQ and DEAQ by human liver microsomes (HLM) and to characterize the CYPs involved in bioactivation of AQ and DEAQ. Methods Glutathione was used to trap reactive metabolites formed in incubations of AQ and DEAQ with HLM and recombinant human cytochrome P450s (hCYPs). Kinetics of bioactivation of AQ and DEAQ in HLM and involvement of hCYPs were characterized by measuring corresponding glutathione conjugates (AQ‐SG and DEAQ‐SG) using a high‐performance liquid chromatography method. Results Bioactivation of AQ and DEAQ in HLM both exhibited Michaelis–Menten kinetics. For AQ bioactivation, enzyme kinetical parameters were K m , 11.5 ± 2.0 μmol l –1 , V max , 59.2 ± 3.2 pmol min −1 mg −1 and CL int , 5.15 μl min −1 mg −1 . For DEAQ, parameters for bioactivation were K m , 6.1 ± 1.3 μmol l –1 , V max , 5.5 ± 0.4 pmol min −1 mg −1 and CL int 0.90 μl min −1 mg −1 . Recombinant hCYPs and inhibition studies with HLM showed involvement of CYP3A4, CYP2C8, CYP2C9 and CYP2D6 in bioactivation. Conclusions The major metabolite DEAQ is likely to be quantitatively more important than AQ with respect to hepatic exposure to reactive metabolites in vivo . High expression of CYP3A4, CYP2C8, CYP2C9, and CYP2D6 may be risk factors for hepatotoxicity caused by AQ‐therapy.
33
Christopher Southan, Joanna L Sharman, Helen E. Benson et al. · Nucleic Acids Research · 2015 · 1K citations · Full text
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes
S P H Alexander, Doriano Fabbro, Eamonn Kelly et al. · British Journal of Pharmacology · 2015 · 603 citations · Full text
Amodiaquine induced agranulocytosis and liver damage.
K Neftel, W Woodtly, M. Schmid et al. · BMJ · 1986 · 292 citations · Full text
Veterinary Medicine, Infectious Diseases, Pharmacotherapy +12
Xueqing Li, Anders Björkman, Tommy B. Andersson et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 285 citations
Xueqing Li, Anders Bj�rkman, Tommy B. Andersson et al. · European Journal of Clinical Pharmacology · 2003 · 232 citations